Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass
spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell
lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and
antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of
CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of
CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
Keywords: Breast cancer, chemokine, CXCL3, migration, proteomics, secretome.
Rights & PermissionsPrintExport